Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2Phase 1 1

Status

Recruiting 2Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Endocrine 5NET 2Gastrointestinal 1

Conditions

Lymphoma 138Lymphoma, Non-Hodgkin 84Lymphoma, Large B-Cell, Diffuse 83Small Cell Lung Carcinoma 78Hodgkin Disease 61Precursor Cell Lymphoblastic Leukemia-Lymphoma 59Leukemia 57Burkitt Lymphoma 56Lung Neoplasms 49Lymphoma, Follicular 47Lymphoma, Mantle-Cell 44Leukemia, Myeloid, Acute 41Lymphoma, Large-Cell, Immunoblastic 40Multiple Myeloma 33Leukemia, Lymphocytic, Chronic, B-Cell 33Carcinoma, Non-Small-Cell Lung 30Recurrence 26Neuroblastoma 25Lymphoma, B-Cell, Marginal Zone 25Central Nervous System Neoplasms 24Ovarian Neoplasms 18Sarcoma 17Brain Neoplasms 17Dendritic Cell Sarcoma, Interdigitating 16Congenital Abnormalities 16Lymphoma, Large-Cell, Anaplastic 15Breast Neoplasms 15Testicular Neoplasms 14Neoplasms, Plasma Cell 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13

Interventions

Everolimus 9Cisplatin 8Temozolomide 6Nivolumab 5Etoposide 5Carboplatin 5Bevacizumab 5lutetium Lu 177 dotatate 4Capecitabine 4pembrolizumab 3Irinotecan 3sintilimab 2dostarlimab 2cabozantinib 2azaspirane 2avelumab 2atezolizumab 2Paclitaxel 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Ipilimumab 2Immunoglobulin G 2IFL protocol 2Fluorouracil 2Fluorodeoxyglucose F18 2Disulfides 2zimberelimab 1surufatinib 1selinexor 1pertuzumab 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Neuroendocrine × Etoposide × Clear all
NCT06406465 2026-06-05

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

NCT04268121 2025-07-23

NEONEC

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2 Recruiting
78 enrolled
EndocrineGastrointestinal

Gastrointestinal Neoplasms, Carcinoma, Neuroendocrine

NCT00193531 2023-04-11

Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma

SCRI Development Innovations, LLC

Phase 2 Completed
100 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT05076786 2021-11-03

Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma

Peking Union Medical College Hospital

Phase 2 Unknown
28 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡